Literature DB >> 682354

Fatal Rocky Mountain spotted fever.

M A Hattwick, H Retailliau, R J O'Brien, M Slutzker, R E Fontaine, B Hanson.   

Abstract

Forty-four fatal cases of Rocky Mountain spotted fever (RMSF) occurring in 1974 were compared with 50 nonfatal cases of similar age, sex, date of onset, and place of occurrence. Diagnosis and initiation of treatment in fatal cases were substantially delayed compared with nonfatal cases. Several reasons for this delay were identified: (1) the rash appeared later in the course of illness in the fatal cases, often not until the patient was terminal, (2) a history of tick bite was less often obtained during life or obtained late in the clinical course in fatal cases, and (3) initial nonspecific symptoms or unexpected symptoms led to an initial diagnosis of more common diseases. Only two fatal cases were treated with either tetracycline or chloramphenicol before the sixth day of illness. Presumptive diagnosis of RMSF and initiation of tetracycline therapy before onset of rash may be necessary to reduce mortality.

Entities:  

Mesh:

Year:  1978        PMID: 682354

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  15 in total

1.  The Rickettsia conorii autotransporter protein Sca1 promotes adherence to nonphagocytic mammalian cells.

Authors:  Sean P Riley; Kenneth C Goh; Timothy M Hermanas; Marissa M Cardwell; Yvonne G Y Chan; Juan J Martinez
Journal:  Infect Immun       Date:  2010-02-22       Impact factor: 3.441

Review 2.  Rocky Mountain spotted fever: a disease in need of microbiological concern.

Authors:  D H Walker
Journal:  Clin Microbiol Rev       Date:  1989-07       Impact factor: 26.132

3.  Interleukin-1 alpha production during Rickettsia rickettsii infection of cultured endothelial cells: potential role in autocrine cell stimulation.

Authors:  L A Sporn; V J Marder
Journal:  Infect Immun       Date:  1996-05       Impact factor: 3.441

Review 4.  Tick-borne encephalopathies : epidemiology, diagnosis, treatment and prevention.

Authors:  Göran Günther; Mats Haglund
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

5.  Quantitative analyses of variations in the injury of endothelial cells elicited by 11 isolates of Rickettsia rickettsii.

Authors:  M E Eremeeva; G A Dasch; D J Silverman
Journal:  Clin Diagn Lab Immunol       Date:  2001-07

Review 6.  Tick-borne infections in children: epidemiology, clinical manifestations, and optimal management strategies.

Authors:  Steven C Buckingham
Journal:  Paediatr Drugs       Date:  2005       Impact factor: 3.022

7.  Risk factors for fatal outcome from rocky mountain spotted Fever in a highly endemic area-Arizona, 2002-2011.

Authors:  Joanna J Regan; Marc S Traeger; Dwight Humpherys; Dianna L Mahoney; Michelle Martinez; Ginny L Emerson; Danielle M Tack; Aimee Geissler; Seema Yasmin; Regina Lawson; Velda Williams; Charlene Hamilton; Craig Levy; Ken Komatsu; David A Yost; Jennifer H McQuiston
Journal:  Clin Infect Dis       Date:  2015-02-19       Impact factor: 9.079

8.  Effect of synthetic protease inhibitors of the amidine type on cell injury by Rickettsia rickettsii.

Authors:  D H Walker; R R Tidwell; T M Rector; J D Geratz
Journal:  Antimicrob Agents Chemother       Date:  1984-05       Impact factor: 5.191

9.  Evaluation of latex-Rickettsia rickettsii test for Rocky Mountain spotted fever in 11 laboratories.

Authors:  K E Hechemy; E E Michaelson; R L Anacker; M Zdeb; S J Sasowski; K T Kleeman; J M Joseph; J Patel; J Kudlac; L B Elliott
Journal:  J Clin Microbiol       Date:  1983-10       Impact factor: 5.948

10.  Myocardial disease in Rocky Mountain spotted fever: clinical, functional, and pathologic findings.

Authors:  J Marin-Garcia; D M Mirvis
Journal:  Pediatr Cardiol       Date:  1984 Apr-Jun       Impact factor: 1.655

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.